These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 10336506)

  • 41. Comparison of two population pharmacokinetic programs, NONMEM and P-PHARM, for tacrolimus.
    Staatz CE; Tett SE
    Eur J Clin Pharmacol; 2002 Dec; 58(9):597-605. PubMed ID: 12483452
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ocular safety and pharmacokinetics study of FK506 suspension eye drops after corneal transplantation.
    Yuan J; Zhai JJ; Huang X; Zhou SY; Chen JQ
    J Ocul Pharmacol Ther; 2012 Apr; 28(2):153-8. PubMed ID: 22136074
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Quantitative relationship between myocardial concentration of tacrolimus and QT prolongation in guinea pigs: pharmacokinetic/pharmacodynamic model incorporating a site of adverse effect.
    Minematsu T; Ohtani H; Yamada Y; Sawada Y; Sato H; Iga T
    J Pharmacokinet Pharmacodyn; 2001 Dec; 28(6):533-54. PubMed ID: 11999291
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Local drug delivery to composite tissue allografts.
    Gruber SA; Shirbacheh MV; Jones JW; Barker JH; Breidenbach WC
    Microsurgery; 2000; 20(8):407-11. PubMed ID: 11150992
    [No Abstract]   [Full Text] [Related]  

  • 45. Pharmacokinetic advantages of a newly developed tacrolimus oil-in-water-type emulsion via the enteral route.
    Uno T; Kazui T; Suzuki Y; Hashimoto H; Suzuki K; Muhammad BA
    Lipids; 1999 Mar; 34(3):249-54. PubMed ID: 10230718
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The isolated hind limb preparation as a drug distribution model.
    Casquero-Dorado AC; Sánchez-Navarro A
    Methods Find Exp Clin Pharmacol; 1996 Sep; 18(7):453-8. PubMed ID: 8900218
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetic animal PET study of FK506 as a potent neuroprotective agent.
    Murakami Y; Takamatsu H; Noda A; Osoda K; Ichise R; Tatsumi M; Tabata K; Sawamoto T; Nishimura S
    J Nucl Med; 2004 Nov; 45(11):1946-9. PubMed ID: 15534067
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Distribution of pneumococcus-induced augmentation of tissue leukostasis in rabbits: specificity for the pulmonary vascular bed.
    Goldblum SE; Reed WP
    J Lab Clin Med; 1985 Mar; 105(3):374-9. PubMed ID: 3973472
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetics of FK506 in liver transplant recipients after continuous intravenous infusion.
    Jain AB; Abu-Elmagd K; Abdallah H; Warty V; Fung J; Todo S; Starzl TE; Venkataramanan R
    J Clin Pharmacol; 1993 Jul; 33(7):606-11. PubMed ID: 7690047
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An in vitro flow model to study streaming during pelvic intra-arterial drug infusions.
    Lutz RJ; Epstein AH; Cook JA; Dedrick RL
    Gynecol Oncol; 1995 Nov; 59(2):288-96. PubMed ID: 7590489
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cardiotoxicity of long-term intravenous administration of FK506 in rabbits: dose relationship and recovery after discontinuance.
    Nomoto S; Fujiwara H; Ban T; Ohara K
    Transplant Proc; 1994 Apr; 26(2):855-7. PubMed ID: 7513477
    [No Abstract]   [Full Text] [Related]  

  • 52. Tacrolimus (FK506): validation of a sensitive enzyme-linked immunosorbent assay kit for and application to a clinical pharmacokinetic study.
    Lee JW; Sukovaty RL; Farmen RH; Dressler DE; Alak A; Bekersky I
    Ther Drug Monit; 1997 Apr; 19(2):201-7. PubMed ID: 9108651
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The effect of FK506 and cyclosporin A on antigen-induced arthritis.
    Blackham A; Griffiths RJ
    Clin Exp Immunol; 1991 Nov; 86(2):224-8. PubMed ID: 1718639
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Improvement and assessment of enzyme-linked immunosorbent assay to detect low FK506 concentrations in plasma or whole blood within 6 hours.
    Wallemacq PE; Firdaous I; Hassoun A
    Clin Chem; 1993 Jun; 39(6):1045-9. PubMed ID: 7684956
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The pharmacokinetic benefits of newly developed liposome-incorporated FK506.
    Ko S; Nakajima Y; Kanehiro H; Yoshimura A; Nakano H
    Transplantation; 1994 Nov; 58(10):1142-4. PubMed ID: 7526494
    [No Abstract]   [Full Text] [Related]  

  • 56. FK506 (tacrolimus), a novel immunosuppressant in organ transplantation: clinical, biomedical, and analytical aspects.
    Wallemacq PE; Reding R
    Clin Chem; 1993 Nov; 39(11 Pt 1):2219-28. PubMed ID: 7693372
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetics of FK506 after intravenous and oral administration in patients awaiting renal transplantation.
    Gruber SA; Hewitt JM; Sorenson AL; Barber DL; Bowers L; Rynders G; Arrazola L; Matas AJ; Rosenberg ME; Canafax DM
    J Clin Pharmacol; 1994 Aug; 34(8):859-64. PubMed ID: 7525661
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The interossei muscles of manus and pes in rabbit.
    Wojnar T
    Folia Morphol (Warsz); 1996; 55(1):57-63. PubMed ID: 8908786
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hypothalamic and brachial nerve effects on circulation of isolated canine forelimb,
    Menninger RP; Baker CH
    Am J Physiol; 1976 Mar; 230(3):797-803. PubMed ID: 1266985
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The rabbit as an experimental model for regional chemotherapy. 1. Intra-arterial hindlimb infusion.
    Davidson T; Wallace J; Carnochan P
    Lab Anim; 1986 Oct; 20(4):343-6. PubMed ID: 3773441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.